A randomized, double-blind, placebo-controlled phase 1 clinical trial to determine safety and immunogenicity of a pichia pastoris-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine in healthy Chinese women aged 9–45 years
Latest Information Update: 19 Apr 2023
At a glance
- Drugs Human papillomavirus 16/18 vaccine recombinant bivalent Xiamen Innovax (Primary)
- Indications Human papillomavirus infections
- Focus Adverse reactions; Pharmacodynamics
- 19 Apr 2023 New trial record
- 13 Apr 2023 Results published in the Vaccine